Peter Lynch · Growth at a reasonable price (GARP)
Is Vertex Pharmaceuticals Incorporated (VRTX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
61/100
Mitigé
4/6 critères validés
Les critères de Peter Lynch, appliqués à VRTX
PEG ≤ 1.0
clé1.85
EPS CAGR ≥ 15%
clé14.2%
Revenue CAGR ≥ 10%
12.4%
Net margin > 0
35.4%
Comment VRTX se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$127.93B
PER (TTM)
26.2x
ROIC (TTM)
17.74%
Marge brute
86.28%
Autres analyses Peter Lynch
Questions fréquentes
What is VRTX's Peter Lynch fit score?
VRTX scores 61/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own VRTX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends VRTX.
How often is this score updated?
VRTX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande VRTX personnellement.
